The synthetic biopharmaceonceline (Carrimycin) is used to treat COVID-19: The FDA has allowed phase III clinical trials

Carrimycin has become the world's first synthetic biologic drug for patients with severe COVID-19, and the U.S. Food and Drug Administration (FDA) has allowed Phase III clinical trials of Carrimycin's treatment of COVID-19.
data have shown that Carrimycin can effectively treat patients with severe COVID-19 and help them recover from severe symptoms within 14 days.
phase III clinical trials approved by the FDA will begin in January 2021 for a period of six months.
in the United States, Argentina, Brazil, Colombia, India, Mexico, Peru, the Philippines and Ukraine.
, as a pandemic occurs, the location can be adjusted.
the trial will involve 300 patients, half in the experimental group and the other half in the control group.
, Carrimycin has anti-viral, anti-inflammatory and anti-fibrosis effects in addition to antibacterial effects.
originally designed to treat bacterial-induced adult community-borne infections.
is a drug developed by Shenyang Tonglian Group using synthetic biology technology in China.
tests in early 2020 have shown that it has a strong anti-coronavirus effect that inhibits the replication of SARS-CoV-2 in cells.
。